-transparent.png){kind=logo}
Short-term treatment with doxorubicin, cytarabine, and 6-thioguanine was given to 91 consecutive adults with acute myelogenous leukaemia. Fifty patients received high doses (regimen I) and 41 very high doses (regimen II). Where possible, six treatment cycles were given (total dose of doxorubicin 450 mg/m2) regardless of the number of cycles required to achieve complete remission. No additional treatment was given. The remission rate was significantly higher with regimen I than with regimen II (34/50 compared with 15/41, p less than 0.01), the latter, more intensive regimen being associated with a greater incidence of fatal infection (13/41 compared with 5/50, p less than 0.01). Duration of remission was, however, significantly longer with regimen II (p less than 0.05); the median has not yet been reached after a minimum follow-up of two years. Intensive short-term treatment is a feasible strategy for the treatment of acute myelogenous leukaemia.
R Bell, and
A Z Rohatiner, and
M L Slevin, and
J M Ford, and
H S Dhaliwal, and
G Henry, and
B G Birkhead, and
J A Amess, and
J S Malpas, and
T A Lister
January 1992,
Leukemia,
R Bell, and
A Z Rohatiner, and
M L Slevin, and
J M Ford, and
H S Dhaliwal, and
G Henry, and
B G Birkhead, and
J A Amess, and
J S Malpas, and
T A Lister
January 1997,
Journal of internal medicine. Supplement,
R Bell, and
A Z Rohatiner, and
M L Slevin, and
J M Ford, and
H S Dhaliwal, and
G Henry, and
B G Birkhead, and
J A Amess, and
J S Malpas, and
T A Lister
February 1988,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R Bell, and
A Z Rohatiner, and
M L Slevin, and
J M Ford, and
H S Dhaliwal, and
G Henry, and
B G Birkhead, and
J A Amess, and
J S Malpas, and
T A Lister
April 1984,
Lancet (London, England),
R Bell, and
A Z Rohatiner, and
M L Slevin, and
J M Ford, and
H S Dhaliwal, and
G Henry, and
B G Birkhead, and
J A Amess, and
J S Malpas, and
T A Lister
March 1984,
Lancet (London, England),
R Bell, and
A Z Rohatiner, and
M L Slevin, and
J M Ford, and
H S Dhaliwal, and
G Henry, and
B G Birkhead, and
J A Amess, and
J S Malpas, and
T A Lister
December 1977,
Lancet (London, England),
R Bell, and
A Z Rohatiner, and
M L Slevin, and
J M Ford, and
H S Dhaliwal, and
G Henry, and
B G Birkhead, and
J A Amess, and
J S Malpas, and
T A Lister
November 1973,
British journal of cancer,
R Bell, and
A Z Rohatiner, and
M L Slevin, and
J M Ford, and
H S Dhaliwal, and
G Henry, and
B G Birkhead, and
J A Amess, and
J S Malpas, and
T A Lister
July 1974,
Irish journal of medical science,
R Bell, and
A Z Rohatiner, and
M L Slevin, and
J M Ford, and
H S Dhaliwal, and
G Henry, and
B G Birkhead, and
J A Amess, and
J S Malpas, and
T A Lister
August 1973,
The British journal of cancer. Supplement,
R Bell, and
A Z Rohatiner, and
M L Slevin, and
J M Ford, and
H S Dhaliwal, and
G Henry, and
B G Birkhead, and
J A Amess, and
J S Malpas, and
T A Lister
February 1998,
Critical reviews in oncology/hematology,
